Zhong S, Thompson M, Cowling B
Influenza Other Respir Viruses. 2025; 19(3):e70052.
PMID: 40045876
PMC: 11883281.
DOI: 10.1111/irv.70052.
Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C
Front Immunol. 2025; 16:1519866.
PMID: 39958330
PMC: 11827429.
DOI: 10.3389/fimmu.2025.1519866.
Alpizar Y, Dallmeier K
Nat Microbiol. 2025; 10(2):277-278.
PMID: 39849084
DOI: 10.1038/s41564-024-01921-5.
Jacobs B, Leroux-Roels I, Bruhwyler J, Groth N, Waerlop G, Janssens Y
Vaccines (Basel). 2025; 12(12.
PMID: 39772052
PMC: 11728545.
DOI: 10.3390/vaccines12121391.
Flores Malavet V, Dhume K, Satchmei A, Arvelo A, Beaird A, Annamalai S
J Clin Invest. 2025; 135(1).
PMID: 39744951
PMC: 11684801.
DOI: 10.1172/JCI179230.
Targets of influenza human T-cell response are mostly conserved in H5N1.
Sidney J, Kim A, de Vries R, Peters B, Meade P, Krammer F
mBio. 2024; 16(2):e0347924.
PMID: 39714185
PMC: 11796400.
DOI: 10.1128/mbio.03479-24.
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2.
Ramirez S, Lopez P, Faraji F, Parikh U, Heaps A, Ritz J
JCI Insight. 2024; 9(24).
PMID: 39704169
PMC: 11665554.
DOI: 10.1172/jci.insight.186078.
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
Bozkus C, Brown M, Velazquez L, Thomas M, Wilson E, ODonnell T
bioRxiv. 2024; .
PMID: 39484455
PMC: 11527131.
DOI: 10.1101/2024.10.23.619918.
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination.
Notarbartolo S
Vaccines (Basel). 2024; 12(10).
PMID: 39460293
PMC: 11511197.
DOI: 10.3390/vaccines12101126.
Inno4Vac Workshop Report Part 2: RSV-Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK.
Waldock J, Cox R, Engelhardt O, Ascough S, Osterhaus A, Rimmelzwaan G
Influenza Other Respir Viruses. 2024; 18(10):e70013.
PMID: 39440808
PMC: 11497170.
DOI: 10.1111/irv.70013.
Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.
Vatzia E, Paudyal B, Dema B, Carr B, Sedaghat-Rostami E, Gubbins S
NPJ Vaccines. 2024; 9(1):188.
PMID: 39397062
PMC: 11471855.
DOI: 10.1038/s41541-024-00989-8.
Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".
Krammer F, Katz J, Engelhardt O, Post D, Roberts P, Sullivan S
Influenza Other Respir Viruses. 2024; 18(10):e13314.
PMID: 39380156
PMC: 11461279.
DOI: 10.1111/irv.13314.
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.
Zheng H, Li C, Zheng X, Jiang H, Li Y, Yao A
Front Immunol. 2024; 15:1461419.
PMID: 39328415
PMC: 11424439.
DOI: 10.3389/fimmu.2024.1461419.
Development of Influenza-Specific CD4 T Cell-Mediated Immunity in Children Following Inactivated Influenza Vaccination.
Shannon I, Huertas N, White C, Yang H, Nayak J
J Pediatric Infect Dis Soc. 2024; 13(10):505-512.
PMID: 39269455
PMC: 11534002.
DOI: 10.1093/jpids/piae095.
Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.
Huang L, Tang W, He L, Li M, Lin X, Hu A
Nat Commun. 2024; 15(1):6802.
PMID: 39122688
PMC: 11315933.
DOI: 10.1038/s41467-024-51182-3.
Immunological characteristics of a recombinant alphaherpesvirus with an envelope-embedded protein of circovirus.
Lu C, Li H, Chen W, Li H, Ma J, Peng P
Front Immunol. 2024; 15:1438371.
PMID: 39081314
PMC: 11286414.
DOI: 10.3389/fimmu.2024.1438371.
Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge.
Malouli D, Tiwary M, Gilbride R, Morrow D, Hughes C, Selseth A
Nat Commun. 2024; 15(1):6007.
PMID: 39030218
PMC: 11272155.
DOI: 10.1038/s41467-024-50345-6.
Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.
Vieira Antao A, Oltmanns F, Schmidt A, Viherlehto V, Irrgang P, Rameix-Welti M
Front Immunol. 2024; 15:1376395.
PMID: 38975350
PMC: 11224462.
DOI: 10.3389/fimmu.2024.1376395.
Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.
Ahmed M, Einhauser S, Peiter C, Senninger A, Baranov O, Eser T
iScience. 2024; 27(6):110138.
PMID: 38974469
PMC: 11225850.
DOI: 10.1016/j.isci.2024.110138.
Timing of Assessment of Humoral and Cell-Mediated Immunity after Influenza Vaccination.
Otani N, Nakajima K, Yamada K, Ishikawa K, Ichiki K, Ueda T
Vaccines (Basel). 2024; 12(6).
PMID: 38932313
PMC: 11209235.
DOI: 10.3390/vaccines12060584.